Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

March 3, 2022

Study Completion Date

March 3, 2022

Conditions

Acute Respiratory Distress Syndrome

Interventions

DRUG

Wharton's jelly derived Mesenchymal stem cells.

IV Wharton's jelly derived Mesenchymal stem cells, two doses

DRUG

Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)

Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo

Trial Locations (2)

Clinical Somer, Rionegro

BioXcellerator, Medellín